It's been a busy few weeks as the FDA continues to approve and release new drugs and various pharmaceuticals products. In recent weeks, the organization has provided updates and approvals for drugs related to Crohn's disease, arthritis, Duchenne muscular dystrophy, as well as alerts and news on a host of related topics.
Some noteworthy items include:
FDA grants accelerated approval to first drug for Duchenne muscular dystrophy: DMD is a debilitating genetic disorder that is manifested in progressive muscle deterioration. Approval for a new drug to treat the disease, Exondys 51, has been granted approval by the FDA.
Avoiding pharmaceutical scams: Interesting video that provides a warning to those in the pharma industry about how to avoid scams.
Amjevita approved to treat inflammatory diseases: Last week, the FDA approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.
Updates on recent drug shortages: A variety of drugs have been discontinued due to shortages, while other previously at-risk situations have been resolved.
We encourage you to check back as we'll continue to keep you updated on news and events happening in the life sciences. Please also check out how Qualio QMS is helping companies in the life sciences address FDA testing and validation with a free 14-day trial of our solution.